PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶:
A61K 39/00, 39/395, 38/18, C07K 14/475

(11) International Publication Number:

WO 96/18413

(43) International Publication Date:

20 June 1996 (20.06.96)

(21) International Application Number:

PCT/GB95/02807

A1

(22) International Filing Date:

1 December 1995 (01.12.95)

(30) Priority Data:

9425060.2

13 December 1994 (13.12.94) GB

(71) Applicant: THE UNIVERSITY OF BIRMINGHAM [GB/GB]; P.O. Box 363, Edgbaston, Birmingham B15 2TT (GB).

(72) Inventor: YOUNG, Lawrence, Sterling; 20 County Park Avenue, Halesowen, West Midlands B62 8SP (GB).

(74) Agents: PEARCE, Anthony, Richmond et al.; Marks & Clerk, Alpha Tower, Suffolk Street Queensway, Birmingham B1 1TT (GB).

(81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

With an indication in relation to a deposited microorganism furnished under Rule 13bis separately from the description.

Date of receipt by the International Bureau:

25 January 1996 (25.01.96)

(54) Title: CARCINOMA TREATMENT

(57) Abstract

For the treatment of carcinomas in epithelial cells and for the prevention of epithelial cell proliferation, use is made of a CD40 receptor binder. The CD40 may be used in conjunction with at least one antineoplastic agent and/or CD40 inducer.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

Austria	GB	United Kingdom	MR	Mauritania
Australia	GE	Georgia		Malawi
Barbados	GN	Guinea	NE	Niger
	GR	Greece	NL	Netherlands
	HU	Hungary	NO	Norway
	IE	Ireland	NZ	New Zealand
	IT	Italy	PL	Poland
	JP	Japan	PT	Portugal
	KE	-	RO	Romania
		•	RU	Russian Federation
			SD	Sudan
		of Korea	SE	Sweden
-	K D	0	SI	Slovenia
			SK	Slovakia
			SN	Senegal
			-	Chad
				Togo
		•		Tajikistan
· ·			_	Trinidad and Tobago
•				Ukraine
		•	-	United States of America
•		•		Uzbekistan
Finland				Viet Nam
France	MN	Mongolia	V.	A ICT LABITE
Gabon				
	Australia Barbados Belgium Burkina Faso Bulgaria Benin Brazil Belarus Canada Central African Republic Congo Switzerland Côte d'Ivoire Cameroon China Czechoslovakia Czech Republic Germany Denmark Spain Finland France	Australia GE Barbados GN Belgium GR Burkina Faso HU Bulgaria IE Benin IT Brazil JP Belarus KE Canada KG Central African Republic KP Congo Switzerland KR Côte d'Ivoire KZ Cameroon LI China LK Czechoslovakia LU Czech Republic LV Germany MC Denmark MD Spain MG Finland ML France MN	Australia Barbados Belgium Belgium GR Greece Burkina Faso Bulgaria Benin Brazil Benin Brazil Belarus Canada Central African Republic Congo Switzerland Côte d'Ivoire Cameroon LI Cameroon LI Cameroon LI Cinha Czechoslovakia Czech Republic Cermany Cermany MC Cermany MC Monaco Denmark Spain MG Madagascar Finland France MN Mongolia MU Mungary Greece Hungary Hungary Ireland KE Kenya Cweece KE Kenya KE Kenya Ken	Australia GE Georgia MW Barbados GN Guinea NE Belgium GR Greece NL Burkina Faso HU Hungary NO Bulgaria IE Ireland NZ Benin IT Italy PL Brazil JP Japan PT Belarus KE Kenya RO Canada KG Kyrgystan RU Central African Republic KP Democratic People's Republic SD Congo of Korea SE Switzerland KR Republic of Korea SI Côte d'Ivoire KZ Kazakhstan SK Cameroon LI Liechtenstein SN China LK Sri Lanka TD Czechoslovakia LU Luxembourg TG Czech Republic MC MC Monaco TT Germany MC Monaco TT Denmark MD Republic of Moldova UA Spain MG Madagascar US Finland ML Mali UZ France MN Mongolia

1

CARCINOMA TREATMENT

This invention relates mainly to carcinoma treatment and is more particularly concerned with the treatment of carcinomas in epithelial cell systems, although the present invention, in its broadest aspect, relates generally to the prevention of epithelial cell proliferation.

It is known to treat carcinomas in epithelial cell systems using antineoplastic agents which are intended to induce apoptosis. Examples of such agents include cytokines and growth factors such as transforming growth factor β_1 (TGF- β_1), anti-Fas, and tumour necrosis factor- α (TNF- α) and other antineoplastic agents such as interferon- γ (IFN- γ), cis-platin, mitomycin C, cyclophosphamide, actinomycin D, doxorubicin, vincristine, etoposide, 5-fluorouracil, methotrexate and irradiation agents. However, there is a continuing need for other drugs for treatment of carcinomas in epithelial cell systems and/or for enhancing the effect of existing anti-neoplastic agents.

In a first aspect, the present invention resides in the use of a CD40 receptor binder for the manufacture of a medicament for the prevention of epithelial cell proliferation or for the treatment of carcinomas in epithelial cell systems.

In a second aspect, the present invention resides in the use of a CD40 receptor binder in the manufacture of a medicament for enhancing the susceptibility of neoplastic epithelial cells to anti-neoplastic drug-induced apoptosis.

In a third aspect, the present invention resides in the use of a CD40 receptor binder in combination with a CD40 inducer for the prevention of epithelial cell proliferation or for the treatment of carcinomas in epithelial cell systems.

In a fourth aspect, the present invention resides in the use of a CD40 receptor binder in combination with an anti-neoplastic drug for the treatment of carcinomas in epithelial cell systems.

In a fifth aspect, the present invention resides in a method of preventing epithelial cell proliferation, comprising administering a CD40 receptor binder to a human or animal patient.

In a sixth aspect, the present invention resides in a method of treating an epithelial cell carcinoma in a human or animal patient, comprising administering a CD40 receptor binder to the patient.

Preferably, such administration is effected in conjunction with administration of at least one anti-neoplastic agent and/or a CD40 inducer.

The anti-neoplastic agent may be selected from known cytokines and growth factors such as transforming growth factor β_1 (TGF- β_1), anti-Fas, and tumour necrosis factor- α (TNF- α) and other known antineoplastic agents such as interferon- γ (IFN- γ), cis-platin, mitomycin C, cyclophosphamide, actinomycin D, doxorubicin, vincristine, etoposide, 5-fluorouracil, methotrexate and irradiation agents. Such anti-neoplastic agent will normally be administered at a dose rate consistent with the recommended for that particular agent.

The CD40 inducer may be interferon- γ (IFN- γ), tumour necrosis factor- α (TNF- α) or any other known inducer of CD40 expresssion. Such CD40 inducer will normally be used at a dose rate consistent with that recommended for that particular inducer.

CD40 is a 50-kDa type 1 glycoprotein belonging to the nerve growth factor receptor/tumour necrosis factor receptor (NGF-R/TNF-R) family, and is expressed on the surface of B lymphocytes (see Noelle et al., Immunol. Today, 13, 431-433, 1992; and Smith et al., Cell, 76, 959-962, 1994). For both normal and neoplastic B cells prone to enter or be driven into apoptosis, ligation of CD40 provides a potent rescue (survival) signal which is partially mediated through the up-regulation of Bcl-2 expression (see Liu et al., Nature, 342, 929-931, 1989). This effect was shown initially using ligand-mimetic monoclonal antibodies (mAb) and more recently confirmed with recombinant ligand (CD40L) (see Noelle et al., supra).

It is also known that expression of both CD40 and Bcl-2 occurs in normal, basal epithelial cells and in a number of different carcinomas including those of the ovary, nasopharynx, lung and breast (see Young et al., Int. J. Cancer, 43, 786-794, 1989; and Hockenbery et al., Proc. Natl. Acad. Sci. USA, 88, 6961-6965, 1991). These studies suggest that the CD40 pathway may be active in carcinomas and that the resulting expression of Bcl-2 may protect these tumours from apoptotic cell death including that induced by the cytotoxic drugs used in conventional cancer chemotherapy (see Dive et al., Semin. Cancer Biol, 3, 417-427, 1992). Furthermore, the restricted expression of CD40 and Bcl-2 to the proliferative basal compartment of stratified, squamous epithelium

indicates a possible role for this pathway in regulating normal growth and the apoptotic process of epithelial differentiation.

In view of the above, it was surprising to find that, contrary to the studies in B cells, CD40 stimulation in epithelial cells of either normal or neoplastic origin results in growth arrest and enhanced susceptibility to anti-neoplastic agent-induced apoptosis.

As examples of CD40 binders, there may be used ligand-mimetic monoclonal antibodies, for example G28.5 (a hybridoma available under the Accession No. HB-9110 from the American Type Tissue Culture Collection, Rockville, Maryland, USA), S2C6 (as disclosed by Paulie et al, Cancer Immunology and Immunotherapy, 20, 23-28, 1985), and naturally occuring or engineered forms of CD40 ligands, of which an example is CD40L. CD40L is a 39-kDa type II integral membrane protein with homology to TNF, which can be induced on T cells following their activation via the T cell receptor (see Clark & Ledbetter, Nature, 367, 425-428, 1994). The CD40-CD40L pair are part of an expanding family of interacting receptor-ligand molecules based on the TNF-R/TNF families which are involved in cellular activation and regulation of apoptosis in target cells (Smith et al., supra).

The CD40 binders may be administered by intravenous, subcutaneous or intraperitoneal injection or infusion, or by direct injection into the site of the tumour in purified or humanised form. The dose rate for the CD40 depending upon whether it is a monoclonal antibody or CD40L and may lie in the microgram to milligram range.

Pharmaceutically acceptable carriers (diluents, excipients, etc.) which are used with the CD40 binder can be selected from any of the known carriers for these types of drug and will depend, inter alai, upon the mode of administration. For example, for producing an injectable composition, the carrier may be selected from simple preparations such as phosphate-buffered saline containing human serum albumin to more complex solutions such as cell culture media.

The present invention will now be described in further detail in the following examples and with reference to the accompanying figures, in which:-

Fig 1 is a chart showing the effect of 48 hours treatment with anti-CD40 mAb G28.5 on the growth of ovarian carcinoma cell line A2780, the data representing the mean of triplicate determinations from three independent experiments and being presented as % decrease in survival relative to untreated controls,

Fig 2 is a chart showing that pre-incubation of 2780CP cell line with 150 U/ml IFN- γ for 24 hours induces a 26% decrease in cell growth in the presence of 2 μ g/ml G28.5 mAb,

Fig 3 is a chart showing the effect of time and concentration of G28.5 mAb on the cell growth of an EJ bladder carcinoma cell line,
Fig 4 is a chart showing the effect of anti-CD40 mAb on the growth of Rat-1/CD40 transfectant (Cl.8),

Fig 5 is a chart showing the enhancement of cytotoxicity by the combination of G28.5 mAb and 5 μ M cis-platin in the ovarian carcinoma cell line A2780, cytotoxicity being measured in a 48 hour MTT assay, the data representing the mean of triplicate determinations from three independent experiments and being presented as % decrease in survival relative to untreated controls,

Fig 6 is a chart showing the enhancement of *cis*-platin-induced cytotoxicity in an EJ bladder carcinoma cell line by incubation for 48 hours with 2 µg/ml G28.5 mAb,

Fig 7 is a chart showing the effect of the incubation of Rat-1/CD40 Cl.8 cells with 1µg/ml G28.5 mAb on various concentrations of *cis*-platin, the data representing the mean of triplicate determinations from three independent experiments,

Fig 8 is a chart showing the effect of 48 hours treatment with CD40L on the growth of the ovarian carcinoma cell line A2780, the data representing the mean of triplicate determinations from three independent experiments and being presented as % decrease in survival relative to untreated controls,

Fig 9 is a chart showing the effect of time and concentration of CD40L on the cell growth of an EJ bladder adenocarcinoma cell line,
Fig 10 is a chart showing the effect of CD40L on the growth of a Rat1/CD40 transfectant (Cl.8), and

Fig 11 is a chart showing the enhancement of *cis*-platin-induced cytotoxicity in the EJ bladder carcinoma cell line by incubation for 48 hours with 100 U/ml CD40L.

Example 1

Cell culture

A human ovarian carcinoma cell line A2780 and its *cis*-platin-resistant derivative 2780CP (see Masuda et al., Cancer Res., **50**, 1863-1866, 1990), an EJ bladder carcinoma cell line (Accession No.85061108, European Collection of Animal Cell Cultures, Porton Down, UK) and Rat-1 fibroblasts (Lania et al., Virology, **101**, 217-232, 1980) were continuously maintained in RPMI 1640 medium (GIBCOBRL, Life technologies Ltd, Paisley, Scotland) supplemented with 10% FCS (foetal

calf serum - ICN Flow, Thane, Oxfordshire, England), 2mM glutamine, and the antibiotics, penicillin (1000 U/ml) and streptomycin (1mg/ml) (Sigma Co. Ltd, Poole, Dorset, England) at 37°C in a 5% CO₂ atmosphere.

Rat-1 fibroblasts expressing CD40 were generated by electroporation of the CD40 expression vector (following the procedure described by Stamenkovic et al., EMBO J., 8, 1403-1410, 1989) with a suitable drug resistant plasmid, pUC LTR neo, at a ratio of 10:1. Stable transfectants of Rat 1 cells expressing CD40 were isolated after prolonged exposure to Geneticin G418 antibiotic at which time individual colonies of drugresistant cells were harvested and separately cultured as individual colonies. Samples of such transfectants have been deposited under the provisions of the Budapest Treaty with European Collection of Cell Cultures, Centre for Applied Microbiology and Research, Salisbury, Wiltshire SP4 0JG, Great Britain, on 10 November 1995 under the Accession No. 951110100.

Expression of the CD40 in the above cell lines was confirmed with FACS analysis using the anti-CD40 antibody, G28.5 mAb. Briefly, cells were harvested after trypsinisation, washed in phosphate-buffered saline (PBS) and resuspended in 0.5 µg/ml G28.5 mAb. After 1 hour incubation at 4°C, the cells were washed in PBS and resuspended in 1:50 dilution of FITC-conjugated goat anti-mouse IgG (Sigma Chemical Co. Ltd, Poole, Dorset, England). After a further 30 minute incubation at 4°C, the cells were washed and finally resuspended in 1% paraformaldehyde prior to standard FACS analysis.

Treatment of cells and Assay for Cell Growth

Inhibition of cell proliferation was evaluated using the colorimetric assay of Mossman (see Mossman, J. Immunol. Meths., 65, 55-63, 1983). In brief, cells were plated on a 96 well plate overnight to enter normal cell cycle. Various concentrations of G28.5 mAb were then added and their effect on cell growth was evaluated after an appropriate period of time (48, 72 or 96 hrs) by the addition of 20 μ l of 5 mg/ml MTT (3-(4,4-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) obtained from Sigma, in PBS. The cells were further incubated for 5 hrs at 37°C, formazan crystals thus formed were dissolved in DMSO and the optical density (O.D.) was recorded at 550nm on a Becton Dickinson Multiscan. In a further series of experiments, cells were treated for 2 hrs with various *cis*-platin concentrations with or without G28.5 mAb. The cells were then washed twice in PBS and 200 μ l of fresh medium containing G28.5 mAb. After 48 hours, cell growth was assessed using the MTT assay as described above.

Effect of anti-CD40 mAb on carcinoma cell growth

The effect of the anti-CD40 mAb G28.5 on the cell growth of the A2780,
2780CP and EJ carcinoma cell lines as well as a CD40 Rat-1 transfectant
(Rat-1/CD40 Cl.8) was examined. G28.5 mAb at the optimum
concentration of 10 µg/ml induced a 29% decrease in survival of the

ovarian A2780 cell line relative to control after 48 hrs treatment (Fig. 1).

When the *cis*-platin-resistant 2780CP cell line was treated under similar conditions with G28.5 mAb, no effect was observed. This was probably due to the low level of CD40 expression in this cell line. However, treatment of the 2780CP cell line with 150 U/ml of interferon- γ (IFN γ) for 24 hrs and subsequent incubation with 10 μ g/ml G28.5, induced an approximately 22% decrease in survival consistent with the induction of

CD40 by IFN γ (Fig. 2). Similar effects of CD40 activation were observed with the EJ bladder carcinoma cell line (Fig. 3). The effect of G28.5 mAb on the EJ cell line is both time- and concentration-dependent with maximum effect at 96 hrs where treatment with 2 μ g/ml G28.5 induced a 27% decrease in survival (Fig. 3).

The specificity of the CD40 effect was investigated using Rat-1 fibroblasts expressing a transfected CD40. As demonstrated in Fig. 4, stimulation of CD40 by the G28.4 mAb inhibited cell growth. In the transfectant studied (clone 8), incubation for 48 hrs with 2 μ g/ml G28.5 mAb induce a 22% decrease in cell growth (Fig. 4).

Enhancement of cis-platin-induced cell death by CD40 activation Treatment of the above cell lines with G28.5 mAb enhanced the cytotoxic effect of anti-cancer drugs such as cis-platin. In the A2780 cell line, exposure to 10 μ g/ml G28.5 mAb increased the cell killing effect of 5 μ M cis-platin from 46% to 61% (Fig. 5), which represents a statistically significant effect. Similar results were obtained with the EJ line treated with 5 μ M cis-platin in the presence of 2 μ g/ml G28.5 mAb (Fig. 6).

Treatment of the Rat-1/CD40 Cl.8 cell line with 1 μ g/ml G28.5 mAb also enhanced the cytotoxic effect of *cis*-platin by shifting the IC50 value from 6 μ M (+/- 0.9) to 4.2 μ M (+/- 0.3), representing a 1.6-1.8 fold increase in drug sensitivity (Fig 7). No effect was found in parental untransfected Rat-1 cells).

Example 2

Cell culture

The cell culture techniques described hereinabove in Example 1 were utilised.

Treatment of cells and Assay for Cell Growth

Inhibition of cell proliferation was evaluated using the colorimetric assay of Mossman (Mossman, J. Immunol. Meths. 65, 55-63, 1983). In brief, cells were plated on a 96 well plate overnight to enter normal cell cycle. Various concentrations of CD40L (an engineered soluble form of a CD40 binding ligand (Immunex Research and Development Corporation, 51 University Street, Seattle, Washington, USA) were then added and their effect on cell growth was evaluated after the appropriate period of time (48, 72 or 96 hrs) by the addition of 20 μ l of 5 mg/ml MTT (3-(4,4dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) obtained from Sigma, in PBS. The cells were further incubated for 5 hrs at 37°C, formazan crystals thus formed were dissolved in DMSO and the optical density (O.D.) was recorded at 550nm on a Becton Dickinson Multiscan. In another series of experiments, cells were treated for 2 hrs with various cis-platin concentrations with or without CD40L. The cells were then washed twice in PBS and 200µl of fresh medium containing CD40L. After 48 hours, cell growth was assessed using the MTT assay as described above.

Effect of CD40L on carcinoma cell growth

The effect of the CD40L on the cell growth of the A2780, 2780CP and EJ carcinoma cell lines as well as a CD40 Rat-1 transfectant (Rat-1/CD40 Cl.8) was examined. 100 U/ml of CD40L induced a 36% decrease in survival of the ovarian A2780 cell line relative to control after 48 hrs treatment (Fig. 8). The effect of CD40L on the EJ cell line is both time and concentration-dependent with maximum effect at 96 hrs where

treatment with 100 U/ml CD40L induced a 43% decrease in survival (Fig. 9).


The specificity of the CD40 effect was investigated using Rat-1 fibroblasts expressing a transfected CD40. As demonstrated in Fig. 10, stimulation of CD40 by CD40L inhibited cell growth. In the transfectant studied (clone 8), incubation for 48 hrs with 100 U/ml CD40L induced a 28% decrease (Figure. 10).


Enhancement of cis-platin-induced cell death by CD40 activation Treatment of the EJ carcinoma cell line with 7.5 μ M cis-platin in the presence of 100 U/ml of CD40L showed enhancement of cell death (Figure 11).


CLAIMS


- 1. The use of a CD40 receptor binder for the manufacture of a medicament for the prevention of epithelial cell proliferation or for the treatment of carcinomas in epithelial cell systems.
- 2. The use of a CD40 receptor binder in the manufacture of a medicament for enhancing the susceptibility of neoplastic epithelial cells to anti-neoplastic drug-induced apoptosis.
- 3. The use of a CD40 receptor binder in combination with a CD40 inducer for the prevention of epithelial cell proliferation or for the treatment of carcinomas in epithelial cell systems.
- 4. The use of a CD40 receptor binder in combination with an antineoplastic drug for the treatment of carcinomas in epithelial cell systems.
- 5. The use as claimed in any preceding claim, wherein the CD40 receptor binder is selected from ligand mimetic monoclonal antibodies and naturally occurring or engineered forms of CD40 ligands.
- 6. The use as claimed in any one of claims 1 to 4, wherein the CD40 receptor binder is selected from G28.5 and CD40L.
- 7. A method of preventing epithelial cell proliferation, comprising administering a CD40 receptor binder to a human or animal patient.


- 8. A method of treating an epithelial cell carcinoma in a human or animal patient, comprising administering a CD40 receptor binder to the patient.
- 9. A method as claimed in claim 7 or 8, wherein administration of the CD40 receptor binder is effected in conjunction with administration of at least one anti-neoplastic agent and/or a CD40 inducer.
























FIG 7









page 24

REC'D	25JAN	1996	-
VARO	PCT		

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

CRC Institute for Cancer Studies University of Birmingham Medical School Birmingham, B15 2TH

VIABILITY STATEMENT issued pursuant to Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY identified on the following page

NAME AND ADDRESS OF THE PARTY TO WHOM THE VIABILITY STATEMENT IS ISSUED

I. DEPO	DSITOR	II. IDENTIFICATION OF THE MICROORGANISM
Name: Address:	CRC Institute for Cancer Studies University of Birmingham Medical School Birmingham B15 2TH	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: 951110100 Date of the deposit or of the transfer: 10th November 1995
III. VIAB	ILITY STATEMENT	
The viabion 10/1 X viab		der II above was tested 2. On that date, the said microorganism was
no 1	longer viable	

Indicate the date of the original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).

In the cases referred to in Rule 10.2(a)(ii) and (iii), refer to the most recent viability test.

Mark with a cross the applicable box.

BUDAPEST TREATY ON THE INTERNATIONAL HECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

		٠
W11011	2 5 JAN 1980	
		-
	= -	

INTERNATIONAL FORM

CRC Institute for Cancer Studies University of Birmingham Medical School Birmingham, B15 2TH NAME AND ADDRESS OF DEPOSITOR RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

I. IDEN	TIFICATION OF THE MICROORGANISH	
Identifi DEPOSITO	cation reference given by the	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:
Rat -	1/CD40 Cl.8	951110100
II. SCI	ENTIFIC DESCRIPTION AND/OR PROPOSED	TAXONOHIC DESIGNATION
The micr	oorganism identified under I above w	vas accompanied by:
X a	scientific description	
a	proposed taxonomic designation	
(Mark wit	h a cross where applicable)	
III. RE	CEIPT AND ACCEPTANCE	
This Int	ernational Depositary Authority access received by it on 10/11/95 (da	opts the microorganism identified under I above, ate of the original deposit)
IV. REC	EIPT OF REQUEST FOR CONVERSION	
Deposita: a reques	to convert the original demosit to	vas received by this International ie of the original deposit) and is a deposit under the Budapest Treaty date of receipt of request for conversion)
V. INTE	RNATIONAL DEPOSITARY AUTHORITY	
Name:	Dr A Doyle	Signature(s) of person(s) having the power to represent the International Depositary
Address:	ECACC, CAMR, Porton Down Salisbury, Wilts, SP4 OJG	Authority or of authorized official(s): Date: 13.1.96

Form BP/4 (sole page)

Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired.

IV.	CONDITIONS	UNDER	WHICH	THE	VIABILITY	TEST	HAS	BEEN	PERFORMED ⁴
								•	
v.	INTERNATION	NAL DEPO	OSITAR	(AU	THORITY				
Name:	Dr A	Doyle	-				1 1	to rep	ture(s) of person(s) having the power present the International Depositary
Addre	ss: ECACO Salis	C, CAMR	, Port Wilts,	on SP	Down 4 OJG			Author	A COUNTY OF AUTHORIZED OFFICIAL(s):

 $^{^4}$ Fill in if the information has been requested and if the results of the test were negative.

INTERNATIONAL SEARCH REPORT

Interv nal Application No PCT/GB 95/02807

		PCT/GB 9	5/02807
A. CLASS IPC 6	sification of subject matter A61K39/00 A61K39/395 A61K3	8/18 C07K14/475	
According	to International Patent Classification (IPC) or to both national c	classification and IPC	
	S SEARCHED		
IPC 6	documentation searched (classification system followed by classi A61K C07K	fication symbols)	
Documenta	ation searched other than minimum documentation to the extent	that such documents are included in the fields	searched
Electronic	data base consulted during the international search (name of data	a base and, where practical, search terms used)
C. DOCUM	MENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the	ne relevant passages	Relevant to claim No.
P,Y	BLOOD, vol. 86 (10 SUPPL. 1), 1995 page 318A, Document 1261 M. A. DEGLI-ESPOSTI ET AL. 'CD a potent growth factor, causes of bladder carcinoma cell lines see the whole document	apoptosis	1-9
Y	EP,A,0 585 943 (SQUIBB BRISTOL March 1994 see page 2, line 57 - page 3, l claim 32	ine 13;	1-9
		-/	,
X Furth	ner documents are listed in the continuation of box C.	Patent family members are listed	in annex.
'A' docume conside 'E' earlier diling d' docume which i citation 'O' docume other m' P' docume later the	nt which may throw doubts on priority claim(s) or is cited to establish the publication date of another i or other special reason (as specified) int referring to an oral disclosure, use, exhibition or	"T" later document published after the interpretary date and not in conflict we cited to understand the principle or the invention "X" document of particular relevance; the cannot be considered novel or cannot involve an inventive step when the do "Y" document of particular relevance; the cannot be considered to involve an in document is combined with one or ments, such combination being obvious in the art. "&" document member of the same patent Date of mailing of the international set. 16. 04. 96	th the application but the application but the application be claimed invention be considered to current is taken alone claimed invention ventive step when the topic other such docusts to a person skilled
-	ailing address of the ISA European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Halle, F	

1

INTERNATIONAL SEARCH REPORT

Interr 1al Application No PCT/GB 95/02807

		PCT/GB 95	02007
	tion) DOCUMENTS CONSIDERED TO BE RELEVANT		Relevant to claim No.
Category *	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim 710.
Y	IMMUNOLOGY, vol. 79, no. 3, 1993 pages 445-451, L. FLORES-ROMO ET AL. 'Anti-CD40 antibody stimulates the VLA-4-dependent adhesion of normal and LFA-1-deficient B cells to endothelium' see page 447, left column, line 10 - right column, line 7		1-9
Α	NATURE, vol. 357, no. 6373, 1992 pages 80-82, RICHARD J. ARMITAGE ET AL. 'Molecular and biological characterization of a murine ligand for CD40' see the whole document		
A	INT. J. CANCER, vol. 43, 1989 pages 786-794, L. S. YOUNG ET AL. 'Identification of a human epithelial cell surface protein sharing an epitope with the C3d/Epstein-Barr virus receptor molecule of B lymphocytes' cited in the application see page 791, left column, paragraph 2		

INTERNATIONAL SEARCH REPORT

suformation on patent family members

Intern nal Application No
PCT/GB 95/02807

Patent	Compiler.		
memt		Publication date	
AU-B-	4612093	10-03-94	
CA-A-	2105552	05-03-94	
FI-A-	933862	05-03-94	
HU-A-	69977	28-09-95	
JP-A-	6315383	15-11-94	
NO-A-	933126	07-03-94	
NZ-A-	248569	26-10-95	
ZA-A-	9306491	25-03-94	
	CA-A- FI-A- HU-A- JP-A- NO-A- NZ-A-	CA-A- 2105552 FI-A- 933862 HU-A- 69977 JP-A- 6315383 NO-A- 933126 NZ-A- 248569	